UPMC Hillman Cancer Center

CCSG Acknowledgement

Required CCSG Acknowledgement

The NCI requires that publications acknowledge the Hillman CCSG support, and they are tracking compliance. If a Hillman CCSG-supported Shared Resource provided data used in your publication, please include the following statement in the acknowledgment section of your publication(s):

"This project used the Hillman [insert name(s) of shared resource(s)] that [is/are] supported in part by award P30CA047904."

Shared Resource Directors: Please make sure to include this statement on all of your order forms, contracts, etc. as a reminder to your users to acknowledge the Hillman CCSG support.


Overview

The UPMC Hillman Cancer Center Immunologic Monitoring and Cellular Products Laboratory (IMCPL) is responsible for therapeutic cell product generation (CPL), serial monitoring of immunologic functions (IML) in patients with cancer who are treated with biologic therapies, and banking of blood and tissues for patients on clinical protocols (TPF). The IMCPL plays a critical role in supporting novel investigator-initiated immunotherapy trials at UPMC Hillman Cancer Center.

Cellular Products Immune Monitoring Tissue Procurement